<DOC>
	<DOC>NCT02742805</DOC>
	<brief_summary>The proposed research is intended to determine if supplementation of relatively high dose vitamin D in chronic urticaria patients receiving omalizumab will result in continued symptomatic control of hives after the discontinuation of omalizumab.</brief_summary>
	<brief_title>Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation</brief_title>
	<detailed_description />
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Physician diagnosed chronic urticaria Currently be receiving omalizumab therapy for the treatment of chronic idiopathic urticaria and be well controlled with a USS &lt;25 Not capable of informed consent. Not capable of answering the questionnaire. Subjects with a pure physical urticaria. Pregnant or lactating women. Subjects with hypercalcemia (calcium &gt; 10.3 mg/dl) or renal insufficiency (GFR &lt;50 ml/min). Subjects with prior anaphylaxis to omalizumab. Currently taking high dose vitamin D supplementation. Prior high dose vitamin D supplementation for urticaria with failure. Baseline 25(OH)D &gt;80 ng/ml Subjects with sarcoidosis, hyperparathyroidism, histoplasmosis, lymphoma or tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>hives</keyword>
</DOC>